3-[(1<->-N-METHYLAMINO)ETHYL-N-BENZYL] PYRROLIDINE MONOMETHANESULFONATE

Abstract: This invention provides a novel and useful purification step in the manufacture of a diamine pyrrolidine side chain intermediate for a quinolone antibiotic that allows production of the antibiotic in significantly greater yields and at lower costs than was previously possible. Salts, procedures and processes for preparing them, including the salt disclosed in Formula (A-1), are also disclosed.

Description: -[ ( l " -N-METHYLAMIN0 )ETHYL-N-BENZYL] PYRROLIDINE MONOMETHANESULFONATE Cross-Reference to Related Applications This application claims the benefit of U.S. Provisional Application 60/087,194 filed May 29, 1998, and U.S. Provisional Application 60/101,848 filed September 25, 1998, the respective disclosures of which are hereby incorporated herein by reference. Field of the Invention This invention discloses a novel salt of a pyrrolidine intermediate used in the manufacture of a quinolone antibiotic. Information Disclosure Albright, David E., Jr., "Purification of 3,5-diaminobenzotrifluoride by selective formation of the hydrochloride salt." U.S. 5130490, issued 14 July 1992, assigned to Occidental Chemical Corp., USA. Chiou, Jackson K. S.; Jones, Ronald E., "Separation and recovery of secondary alkyl primary amines." U.S. 3927102, Issued 16 December 1975, assigned to Texaco Inc., USA. Cocker, Wesley; Pratt, A. C; Shannon, P. V. R., "Preparation and the configuration of some stereoisomeric caranylamines." Tetrahedron Lett. (1967), Issue 49, pp. 5017-5020. Dudzinski, Zdzislaw F., "Process of Making Aliphatic amines." U.S. 3436420 issued 1 April 1969, assigned to Millmaster Onyx Corp., USA. Domagala, et. al., "Individual Stereoisomers of Intermediate of 7-[3-(l- Aminoalkyl)-l-Pyrrolidinyl]-Quinolones and Naphthyridones as Antibacterial Agents." US 5,461, 165, issued October 24, 1995, assigned to Warner- Lambert Co., USA. Hayakawa, et. al., "3 -Pyrrolidine Methanamines Wherein the Alpha- Carbon is Substituted by 1 or 2 Lower Alkyl Groups which are Intermediates for Pyridone-Carboxylic Acid Derivatives." US 5,416,222, issued May 16, 1995, assigned to Daiichi Seiyaku Co., Japan. Lerman, Ori, Tennenbaum, Michael, Gal, Erez, Kaspi, Joseph, "Process for the purification of (RR,SS)-2-dimethylamino)methyl-l-(3- methoxyphenyl)cyclohexanol and its salts from the (RS,SR) isomer via acid dehydration and recrystallization " Eur Pat Appl , EP 0778262 A2, Application EP 96-308347 2, Published 11 06 1997, assigned to Chemagis Ltd , Israel McWhorter, William W , Fleck, Thomas J , Pearlman, Bruce, A, "Optically Active 3 -(l-(alkylamino)alkyl)pyrrolidines " PCT/US94/04548, See WO 94/26708, published 24 November 1994, assigned to Pharmacia & Upjohn, Co , USA Pouyet, Bernard, "Purification of aromatic amines " Univ Lyon, Lyons, Fr Purif Inorg Org Mater (1969), 121-4 Editor(s) Zief, Morris Publisher Marcel Dekker, Inc , New York, N Y CODEN 21BVA5 Conference written in English R Stuart Tipson, "Crystallization and Recrystallization" Chapter II, especially pp 396-397 of "Technique of Organic Chemistry, Vol III, Part 1, Separation and Purification " Editor Weissberger, Arnold, Published in 1956 by Interscience Publishers, a division of John Wiley & Sons, London, New York, Sidney, Library of Congress catalog card number 49-48584 Tavare, Narayan S , "Industrial Crystallization, Process Simulation Analysis and Design" pp 1-5 University of Manchester Institute of Science and Technology (UMIST), Manchester, United Kingdom Published in 1995 by Plenum Press, New York, a division of Plenum Publishing Corp , New York, New York, ISBN 0-306-44861-0 Jacob Zabicky, "Detection, determination and characterisation of amines" Chapter 3, pp 87-89 of "The Chemistry of the Amino Group " Editor Patai, Saul, The Hebrew University, Jerusalem, Israel Published in 1968 by Interscience Publishers, a division of John Wiley & Sons, London, New York, Sidney, Library of Congress catalog card number 67-31072, SBN 470 66931 4 BACKGROUND OF THE INVENTION Quinolone type structures are known for their antibacterial properties, and several quinolone antibiotics (e.g. norfloxacin and ciprofloxacin) are on the market. Quinolone antibiotics may be considered as having two main structural components, the quinolone nucleus and side chains covalently bound to that nucleus. The composition of the side chain attached to the quinolone nucleus controls many of the properties of the antibiotic. Properties such as the antibiotic's potency and side effects may be strongly influenced by the structure of the side chain. The manufacture of the side chain is a critical component in the manufacture of the quinolone antibiotic. With some quinolone antibiotics the side chain can be manufactured independently from the quinolone nucleus. This invention discloses a new method of producing a purified intermediate that can then be processed into a side chain intermediate which can be attached to a quinolone nucleus in order to produce a useful antibiotic. Purification steps are very important in the manufacturing of pharmaceutical drugs. Every step in the manufacture of a drug requires expense in the form of operators, equipment and protocols that ensure the proper product is created. The manufacturing process and conditions must comply with both good manufacturing practices and with numerous regulations. Here we disclose a novel and useful purification step in the manufacture of a quinolone antibiotic diamine pyrrolidine side chain intermediate for a quinolone antibiotic that allows production of the antibiotic in significantly greater yields and at lower costs than was previously possible. SUMMARY OF THE INVENTION This invention comprises a compound represented by the name (3R, 1 'S)-3-[(l '-N-methylamino)ethyl-N-benzylpyrrolidine monomethanesulfonate and any of the compounds selected from any of the diastereomers of the salts represented by the formula below, (Formula A) where * indicates an asymmetric carbon atom. Also included are any specific diastereomers selected from any of possible diastereomers of the salt of the formula above, including the 4 diastereomers indicated below. (Formula A-1) Also disclosed are specific salts of formula A-1, including, a salt having the proton (IH) NMR spectra values shown below, IH-NMR (CDC13): 1.3 (d, 3H, J=6), 1.65 (m, IH), 2.0 (m, IH), 2.4-2.7 (m, 4H), 2.65 (s, 3H), 2.7 (s, 3H), 2.8 (m, IH), 3.05 (t, IH, J=9), 3.6 (d, IH, J=13), 3.7 (d, IH, J=13), 7.3 (m, 6H), 7.6 (bs, IH); A salt of formula A-1 having the carbon 13 (13C) NMR spectra values shown below, 13C-NMR (CDC13): 13.69, 30.80, 39.31 (CH3); 26.33, 53.48, 56.86, 59.89 (CH2), 40.01, 58.37, 127.11, 128.26, 128.73 (CH), 138.23 (C) A salt of formula A-1 having a melting point between about 91°C and about 105°C; a salt of formula A-1 having a melting point between about 91°C and about 95°C; and a salt of formula A-1 having a melting point between about 99°C and about 105°C. The invention also discloses procedures for producing a salt having the formula below. (Formula A-1) comprising the steps of a) adding MeSO 3 H to any stereoisomers of the diamine shown below. where a * indicates an asymmetric carbon atom, b) adding sufficient solvent in which the salt is poorly soluble, c) collecting the crystalline diamine MeSO H salt. In more particular, the invention describes a process where the stereoisomers of the diamine are dissolved in an anhydrous organic solvent solution before and when the MeSO 3 H is added; said solvent in which the salt is poorly soluble is also anhydrous and its volume is greater than the volume of the original anhydrous organic solvent (step a); the solution of salt and said solvent are heated and distilled until the volume reduction from distillation is 20% or more, with the distillation temperature being held to a maximum of about 80°C; cooling said heated and distilled mixture, with the temperature being lowered to between about 60°C to 20°C, adding previously prepared seed salt and then cooling the resulting salt solution further by cooling to between about 40 to below -20°C, filtering said solution and collecting the crystals. Crystals can be washed in cool (about 5°C to -10°C) THF and dried again. More particularly, the diamine can be dissolved in CH 2 C1 2 solution before and when the MeSO H is added, and said solvent in which the salt is poorly soluble is THF and the volume of the THF is greater than the volume of original CH 2 C1 2 solvent, and said distillation temperature maximum is about 65°C, said heated and distilled mixture is cooled, with the temperature being lowered to about 45°C, and after said seed salt is added the resulting salt solution is further cooled to between about 20°C to -10°C, and then filtered, and the filtrate is then washed in cool (about 0°C to -5°C) THF, and filtered again. Even more particularly, the heated mixture may be cooled to about 45°C for about 5 - 10 minutes, and when the seed salt is added the resulting salt solution is cooled to about 28°C for about 5 - 10 minutes, then cooled to about 20°C in about 5 min., held at 20°C for about 1 hour, then cooled to about -10 to -5°C in about 30 min. and filtered and then washed with 0°C THF and dried at about 50°C. ADDITIONAL DESCRIPTION OF THE INVENTION AND DESCRIPTION OF THE PREFERRED EMBODIMENTS Definitions CDC1 3 is deuterium substituted carbon tetrachloride. Bn is benzyl or -CH 2 -phenyl. "Diamine" refers to either a specific compound whose formula is shown as a MeSO 3 H salt in Formula A or it can refer to any of the diastereomers shown as benzylated precursors in Formulas C - G, or it may refer to any specific isomers of those compounds. The preferred isomer is shown in Formula A and is the (3R, l'S)-diastereomer. Diastereomer refers to compound with a particular configuration. It is synonymous with enantiomer, stereoisomer, diastereoisomer, diastereomer and diasteriomer, all these terms may be used interchangeably in this document. "NMR" or "nmr" is Nuclear Magnetic Resonance Spectroscopy. "Prediamine" refers to the benzyl derivative precursor of the diamine, or it can refer to any of the diastereomers shown in Formulas C - G, or it may refer to any specific isomers of those compounds. "THF" is tetrahydrofuran. "XRD" is X-Ray Diffraction or Powder X-Ray Diffraction. Units of Measure °C is degree centigrade. g is gram. Hz is Hertz Kj is Equilibria constant for the inhibitor. L is Liter M is molar or moles per liter mg is milligram min is minute mHz is milliHertz mL is milliliter mM is milliMolar or millimoles/liter m/z is mass per unit charge negative numbers may be indicated with a hyphen or "-" before the number nm is nanometers ppm is parts per million rpm is revolutions per minute sec is second slm is standard liters per minute μL or uL is microliter μsec is microsecond Units of measure used should be obvious to one skilled in the art or they can be found in any most reference books. DETAILS OF THE INVENTION This invention describes a process for improving the purification yield of the reaction that starts with a crude prediamine mixture and produces purified diamine, shown in reaction Scheme I, below. Here, diamine is the quinolone antibiotic diamine pyrrolidine side chain intermediate, that would be coupled to the quinolone nucleus. The prediamine is prepared by an asymmetric process which produces a preponderance of the desired enantiomer. Here the (3 , l'S)-enantiomer, shown in Formula A-1, is preferred, but usually when produced it is not 100% isomerically pure. A process for the preparation of pyrrolidine side chain is disclosed in McWhorter, William W.; Fleck, Thomas J.; Pearlman, Bruce, A; "Optically Active 3-(l- (alkylamino)alkyl)pyrrolidines" PCT US94/04548, see WO 94/26708, published 24 November 1994, applicant is Pharmacia & Upjohn Co., USA, the disclosure of which is incorporated by reference herein. Formula A-1, or prediamine-MeSO 3 H, which may be named, (3R, rS)-3-[(r-N-methylamino)ethyl-N-benzylpyrrolidine monomethanesulfonate, is shown below. Formula A-1, or prediamine- MeSO 3 H. In scheme I below, the prediamine may be named, (3R,rS)-3-[(l'-N-methylamino)ethyl-N-berLzylpyrrolidine, it is converted to the diamine which may be named (3R,rS)-3-[(l'-N-methylamino)ethylpyrrolidine. Scheme I H3 Pred amine Typically, in the manufacture of diamine, the purity of prediamine has a large effect on the debenzylation and purification conditions that produce purified diamine. Ordinarily in the typical manufacturing process, prediamine is created in a solution that also includes byproducts or contaminates with the prediamine. Included among these byproducts are various olefinic byproducts. One such olefinic byproduct is described by Formula B, below. Such byproducts differ significantly in structure and are, therefore, relatively easy to reduce or eliminate by purification methods like distillation or pH-controlled liquid-liquid extraction. Formula B The typical manufacturing process also creates small amounts of undesired isomeric forms of prediamine, which are much more difficult to remove. These include the (3S,l'R)-enantiomer, the (3R,1'R)- and (3S,1'S)- diastereomers, and the 3-(2'-N-methylamino)-regioisomers shown as Formulas C - G, below. These isomeric forms are exceedingly similar in structure and reactivity to the desired (3R,l'S)-enantiomer. Unless they are removed from the process, byproducts of this type, as well as byproducts like Formula B, can significantly reduce the purity of the diamine produced and, ultimately, the purity of the final quinolone antibiotic. Therefore, purification steps are needed which efficiently produce purified diamine. Formulas C - G It is well known that purification by crystallization is the preferred method for removing minor contaminates which are structurally similar to the major component. Other purification methods like distillation or chromatography cannot efficiently remove isomers since they have very similar boiling points and retention characteristics. Crystallization separates such mixtures primarily on the basis of the mass of the components. A super- saturated solution of the major component is almost always not saturated in minor components of the mixture. Thus, the crystals formed are enriched in the major component and minor components are retained in solution. The difficulty with crystallizing the diamine is that prediamine and diamine do not crystallize in their free base forms. Previous workers in this area have reported these compounds and similar analogs and they usually suggest isolation of the compounds as oils followed by purification with inefficient chromatography. See for example, Domagala, et. al., in US 5,461,165 and Hayakawa, et. al, in US 5,416,222. Purification by crystallization would be a big improvement but there can be no purification of the diamine by crystallization if the prediamine does not exist in crystalline form. Discovering the conditions and materials that allow the prediamine to crystallize was key to discovering a method to produce pure diamine. Purification of prediamine via crystallization was only possible after preparing an intermediate salt with a stoichiometric amount of methanesulfonic acid (MeSO 3 H). This purification method was the only one shown to reduce the levels of isomeric contaminates like the (3R,l'R)-diastereomer. This corresponded to an increase in the yield of purified diamine as well as purified quinolone antibiotic. The MeSO 3 H salt can be created for any of the diamine isomers (see Formula A, below) and should a process be created where a different diamine isomer was favored, then the MeSO 3 H salt could also be prepared for that isomer, using procedures similar to those described here for the (3R,1'S)- diastereomer. Formula A, below provides a formula that shows the two asymmetric carbon atoms in the prediamine and the covalent bonds are shown as solid lines. Other formula, such as Formula A-1, show the orientation of the relevant covalent bonds, with a dotted line indicating the bond is down, into the paper and a solid wedge shaped line indicating the bond is up out of the paper. See, Formula A- 1 , further below. Formula A, above, where an " * " indicates an asymmetric carbon atom. Crystal forms and purity. It is possible for the purified diamine to exist in different crystal forms. The form of the crystal can vary depending upon very slight differences in manufacture. The rate of heating or cooling, the presence of impurities, the solvents used, temperature, pressure, humidity, even gravity as well as a host of other factors can all affect crystal formation. These factors can also affect melting points of crystals. An impurity in a crystal and/or the precise form of the crystal can all affect at what temperature or range of temperatures a crystal will melt. Here we have created several crystal forms of the desired crystals and provided data to show both proton placements (NMR data) and crystal form structure (XRD data). These examples are intended to illustrate a few of the possible crystal forms and compositions possible. The following example shows one method of making one diasteriomer of Prediamine-MeSO 3 H salt using prediamine which had the olefinic contaminates (like in Formula B) already removed by pH-controlled extraction. However, the process has been shown to also be effective when using typical, crude prediamine. This example is intended to illustrate and not limit the invention described above. One skilled in the art would be expected to make obvious variations and insubstantial changes from the specific conditions provided below. Experimental for purification of prediamine via MeSO^H salt To a solution of partially purified prediamine, purified via pH 8 and pH 12 extractions (15.0 g, about 67.8 mmol, GC 98.7 area %, 1.0% (3R,1'R)- diastereomer), in CH 2 C1 2 (70 ml) at 0-2°C, slowly add MeSO 3 H 6.67 g, 4.50 ml, 69.4 mmol, about 1.02 eq) to maintain 1-8°C (over 7 min). Add THF (anhydrous and stabilized, 150 ml) at 0-10°C (25 min). Distill to 90 ml total volume atmospherically (135 min, max pot temp 65°C). Cool to 45°C (10 min) and seed with previously made salt. Crystals form 2 min later at 40°C. Cool to 28°C (8 min) before applying cold H 2 O bath. Cool to 20°C (5 min) and hold 1 hr. Cool with ice-salt bath to -10 to 0°C (30 min, -8°C) and filter. Wash with cold THF (0°C, 2 x 22 ml). Dry overnight in vacuum oven at 50°C to give crystals (18.95 g, GC 99% with 0.5% (3R,l'R)-diastereomer, about 89% of theory). Dissolve a portion of the salt (18.0 g) in CH 2 C1 (90 ml) and stir with H 2 O (90 ml) while adding 50% aqueous NaOH dropwise to pH 11.8-12 (2.3 ml from pH 7.8 to 11.9). Allow phases to separate, remove the lower CH 2 C1 2 phase, and extract the aqueous phase with CH 2 C1 2 (90 ml, pH still 12). Combine the two CH 2 C1 2 phases and remove solvent by rotovap and high- vacuum pump to give an oil (12.3 g, about 98% recovery). This sample was dissolved in MeOH and hydrogenated to diamine (6.89 g, GC 98% area with 0.5% (3R,l'R)-diastereomer, 99% chemical yield). The resulting salt has the formula of Formula A-1, or prediamine- MeSO 3 H, shown below. Formula A-1, or prediamine- MeSO 3 H. (3R,l'S)-3-[(r-N-methylamino)ethyl-N-benzylpyrrolidine monomethanesulfonate The formation of a prediamine- MeSO 3 H salt can provide an easy method of producing large amounts of relatively pure diamine. Confirmation of the structure of Formula A-1 by NMR spectroscopy Nuclear Magnetic Resonance (NMR) spectroscopy was used to confirm the structure of Formula A. Both proton and 13C NMRs were performed. The equipment parameters and spectra and interpretation are provided here. NMR data were recorded on a Bruker AMX300 operating at 300.13 MHz for the observation of IH and 75.40 MHz for the observation of 13C. Samples were dissolved in, and internally referenced to, CDC13 (IH, d = 7.26; 13C, d = 77.0). One dimensional NMR data were recorded as a 32k complex point data table with a 10,600 Hz sweep width for proton and 20,800 Hz sweep width for carbon. The number of transients and various pulse widths are listed in the appropriate figures. IH experiments were processed with gaussian multiplication and 13C with a 2 Hz exponential multiplication prior to fourier transformation. The spectral data and interpretation provided follow standard abbreviations - d is doublet, m is multiplet, s is singlet, t is triplet, H is hydrogen, J is coupling constant in hertz. The values provided are chemical shifts in ppm (parts per million) from the reference peak. Proton NMR Data Parameters: EXPNO is 11, PROCNO is 1. Acquisition Parameters: SOLVENT is CDC13, AQ is 1.3271240 sec, FIDRES is 0.376760 Hz, DW is 81.0 μsec, RG is 4096, NUCLEUS is IH, HL1 is 1 dB, Dl is 3.0 sec, PI is 10.3 μsec, DE is 101.3 μseα, SFO1 is 300.1351620 MHz, SWH is 6172.84 Hz, TD is 16384, NS is 16 , DS is 2. Processing parameters: SI is 16384, SF is 300.1333581 MHz, WDW is GM, SSB is 0, LB is -0.30 Hz, GB is 0.15, PC is 3.00. Proton NMR spectra and interpretation: IH-NMR (CDC13): 1.3 (d, 3H, J=6), 1.65 (m, IH), 2.0 (m, IH), 2.4-2.7 (m, 4H), 2.65 (s, 3H), 2.7 (s, 3H), 2.8 (m, IH), 3.05 (t, IH, J=9), 3.6 (d, IH, J=13), 3.7 (d, IH, J=13), 7.3 (m, 6H), 7.6 (bs, IH); 13C NMR Data Parameters EXPNO is 14, PROCNO is 1 Acquisition Parameters SOLVENT is CDC 13, AQ is 0 327700 sec, FIDRES is 1 525879 Hz, DW is 20 0 μsec , RG is 4096, NUCLEUS is 13C, HL1 is 1 dB, Dl is 1 0 sec , SI is ldB, P3 is 9 0 μsec , SFO2 is 300 1346670 MHz, D2 is 0 0035714 sec , P4 is 18 0 μsec , PI is 7 0 μsec , P2 is 14 0 μsec , S2 is 22 dB, DE is 25 0 μsec , SF01 is 75 4753020 MHz, SWH is 25000 00 Hz, TD is 16384, P31 is 100 0 μsec , NS is 256, DS is 4 Processing parameters SI is 16384, SF is 75 4685977 MHz, WDW is EM, SSB is 0, LB is 2 00 Hz, GB is 0, PC is 1 40 13 C-NMR spectra and interpretation 13C-NMR (CDC13) 13 69, 30 80, 39 31 (CH3), 26 33, 53 48, 56 86, 59 89 (CH2), 40 01, 58 37, 127 11, 128 26, 128 73 (CH), 138 23 (C) Confirmation of the structure of Formula A-1 by XRD spectroscopy A Rigaku DMAX-A X-ray diffractometer is employed for the acquisition of the powder XRD patterns The instrument is operated with the copper K-L 3 radiation at 1 5406 A The major instrumental parameters are set as follows 40 KV voltage, 30 mA current, beam aperture of 1° and detector aperture (receiving slit) of 0 30° Patterns are scanned over the range of 3-40° two-theta angles with a scan rate of 1 5° two-theta/min (step size of 0 05° and counting time at 2 second/step) Samples are ground to fine powders and packed into an aluminum tray Complete description of the parameters and abbreviations used below may be found in either the operations manual for the Rigaku DMAX-A X-ray diffractometer, or they may be found in most XRD manuals Peak Reports for three different crystals are provided here The first report, below, shows the spectra for a crystal with a melting point between about 99 and 105 °C Number 1 Area Sum 8308 309 STD Center X Height Width Area Qty Name 0 5 834918 1092 0131 8751047 22419034 0 583 0 9 91 10054 383 73329 8273052 10487254 0 991 0 1 1 13072 451 6321 1 585815 94732384 0 1113 1169375 52870474 666675 11414881 0 1169 14795333 17979825 1455302 47967671 0 1479 15921212 14762741 951913 36307695 0 1592 17471698 18558032 1323417 67798383 0 1747 18475686 41045285 503866 75167063 0 1847 19023329 32681195 1237003 97186381 0 1902 19219853 87331139 261395 15285561 0 1922 19605024 27920912 424057 54056151 0 196 19975194 35701175 541624 -5132979 0 1997 21241494 26454923 1175444 10836633 0 2124 22891667 15592777 1301086 60635257 0 2289 23521112 91309385 494843 22295287 0 2352 24133978 10195988 554393 34574773 0 2413 24508086 12646217 392158 33629395 0 2451 25017281 19131805 1519106 63257096 0 2502 25401105 21586944 817443 24849867 0 254 25918957 -8741223 1569454 -3706186 0 2592 26815625 13278142 462531 31495602 0 2681 27092949 12379176 690996 42244557 0 2709 28224462 60042504 859375 19327808 0 2822 28830992 61087875 608551 16768869 0 2883 29488636 3243707 623618 97977263 0 2949 30005232 22275713 582108 70931509 0 30 31122761 25515629 854026 79714945 0 3112 325 92051473 582163 29329946 0 325 33162097 26693974 52954 61269216 0 3316 33745714 71357752 569382 20886694 0 3374 34668382 14645223 992 655167 0 3467 35547222 25587001 609394 68453135 0 3555 35984862 15683937 577744 36357722 0 3598 37268038 2426646 917453 94268565 0 3727 0 37.880357 75.850116 .463806 16.364475 0 37.88 0 38.438983 1012.3131 1.606297 350.42475 0 38.44 0 39.473034 119.39596 .555893 28.845653 0 39.47 The second report, below, shows the spectra for a crystal with a melting point between about 99 and 105°C. Number 2. Area Sum: 13396.29 STD Center X Height Width Area Qty Name 0 5.9715556 7027.6799 1.3933285 1240.5507 0 5.97 0 9.8595943 802.23455 .95033977 157.99408 0 9.86 0 11.128762 962.72309 .83826671 185.32174 0 11.13 0 11.933489 5107.8936 1.1434835 843.2251 0 11.93 0 12.979861 248.5398 .59978733 41.478462 0 12.98 0 14.770327 797.52601 .99394451 164.05737 0 14.77 0 15.223529 158.05241 .49794698 29.780324 0 15.22 0 16.608459 1287.2919 1.0963857 267.2659 0 16.61 0 17.657398 4447.2803 .72198886 1065.9162 0 17.66 0 17.927192 4573.0339 .54387841 819.07926 0 17.93 0 18.884714 4399.7459 .62235323 916.47831 0 18.88 0 19.085128 6096.8224 .50971719 1123.0525 0 19.08 0 19.810571 470.83092 .4129033 60.143712 0 19.81 0 20.200498 4813.3296 .95528902 1137.7599 0 20.2 0 20.964015 186.93076 .40539918 28.206431 0 20.96 0 21.827907 1762.838 .77977651 420.34597 0 21.83 0 22.271059 1275.6447 .58514569 314.27325 0 22.27 0 22.990567 1508.8252 .73054087 315.12441 0 22.99 0 24.015809 5758.6184 1.3634189 1336.4861 0 24.01 0 24.444188 599.2165 .84461837 425.62015 0 24.44 0 25.029239 927.12006 .66213916 207.90402 0 25.03 0 25.818684 1492.6358 .89375199 428.21817 0 25.82 0 26.035822 177.30743 .28641852 26.096782 0 26.03 0 26.413524 4.2728519 .38634407 1.1535085 0 26.41 0 27394792 92609227 76494323 20949965 0 2739 0 28655916 14406638 87687014 40614477 0 2865 0 30127184 70333693 11222087 23153941 0 3013 0 30818846 14260067 52772255 25706841 0 3082 0 31613529 7833234 80394348 18649975 0 3161 0 32213596 37477607 80186508 10873435 0 3221 0 33170833 391 94545542 12511446 0 3317 0 35032308 76362971 40026442 15120593 0 3503 0 35577371 45105412 12308229 18778989 0 3558 0 36349167 36065748 6245618 75278669 0 3635 0 38433815 89570864 89174144 21618376 0 3843 0 39676202 17907396 65 5315 0 3968 The third report, below, shows the spectra for a crystal with a melting point between about 91 and 95°C Number 3 Area Sum 9154 595 STD Center X Height Width Area Qty Name 0 59153846 94401017 10937917 27189777 0 591 0 98864754 42413142 73957126 82445475 0 989 0 11137689 45844108 72857206 90561068 0 1114 0 11736436 29501043 42062792 57883083 0 1174 0 11912097 27045386 35773856 45651294 0 1191 0 14799397 14730095 10211427 28899874 0 148 0 15929309 90803285 76254095 19724495 0 1593 0 16631835 77574021 71458333 18431585 0 1663 0 17518764 14583208 69189122 37716544 0 1752 0 17681298 14013277 17642639 22397892 0 1768 0 17928364 1766818 42884906 38466641 0 1793 0 18493333 198697 40320057 32965388 0 1849 0 1906505 33188726 11921022 15896955 0 1906 0 19617385 23154976 48113491 67113181 0 1962 0 2019373 2687976 8195737 84238561 0 2019 20.571512 164.77539 .25451639 23.855266 0 20.57 21.266521 1431.421 .82361901 613.48087 0 21.27 21.845448 1036.8835 .52982799 258.09355 0 21.84 22.2898 786.16844 .46039375 203.43032 0 22.29 22.922488 979.30254 .74892663 360.64567 0 22.92 23.529706 438.59226 .41670751 110.79993 0 23.53 24.121519 948.97611 .60244684 379.03961 0 24.12 24.48561 1424.7514 .43338209 349.13472 0 24.48 25.039211 1521.3687 .86442201 432.59769 0 25.04 25.418595 201.42547 .28827287 28.952083 0 25.42 27.412277 463 .69236495 122.18741 0 27.41 28.263393 320.80197 .491224 89.646156 0 28.26 28.690079 403.3547 .72602709 151.88305 0 28.69 29.518939 176.73902 .50940204 50.783171 0 29.52 29.990476 199.61121 .68674462 83.839193 0 29.99 31.163587 92.31139 .50992405 19.136831 0 31.16 32.219697 107.07185 .61296813 26.201445 0 32.22 33.177174 302.24777 1.2885351 86.682518 0 33.18 33.7375 59.417303 .56476314 20.061035 0 33.74 35.530078 231.34934 .705873 58.259443 0 35.53 37.27931 108.05567 .78690464 30.966579 0 37.28 38.444396 1006.0711 1.0134273 280.65145 0 38.44 39.670588 88.837647 .9375 33.279688 0 39.67

Claims: Claims: 1. A composition comprising the compound represented by the name (3R,l'S)-3-[(r-N-methylamino)ethyl-N-benzylpyrrolidine monomethanesulfonate. 2. A composition comprising a compound selected from any of the diastereomers of the salts represented by the formula (Formula A) where * indicates an asymmetric carbon atom. 3. A composition comprising a specific diastereomer selected from any of four possible diastereomers of the salt of claim 2, where the four possible diastereomers are indicated below: (Formula A-1) 4. A composition comprising a specific diastereomer selected from the salts of claim 3, said diastereomer having the formula (Formula A-1) 5. A composition comprising the salt of claim 4, said salt having the proton (IH) NMR spectra values shown below: IH-NMR (CDC13): 1.3 (d, 3H, J=6), 1.65 (m, IH), 2.0 (m, IH), 2.4-2.7 (m, 4H), 2.65 (s, 3H), 2.7 (s, 3H), 2.8 (m, IH), 3.05 (t, IH, J=9), 3.6 (d, IH, J=13), 3.7 (d, IH, J=13), 7.3 (m, 6H), 7.6 (bs, IH); 6. A composition comprising the salt of claim 4, said salt having the carbon 13 (13C) NMR spectra values shown below: 13C-NMR (CDC13): 13.69, 30.80, 39.31 (CH3); 26.33, 53.48, 56.86, 59.89 (CH2), 40.01, 58.37, 127.11, 128.26, 128.73 (CH), 138.23 (C). 7. A composition comprising the salt of claim 4, said salt having a melting point between about 91°C and about 105°C. 8. A composition comprising the salt of claim 6, said salt having a melting point between about 91°C and about 95°C. 9. A composition comprising the salt of claim 6, said salt having a melting point between about 99°C and about 105°C. 10. A process for producing the salt having the formula (Formula A- 1 ) comprising the steps of a) adding MeSO 3 H to any stereoisomers of the diamine shown below, where a * indicates an asymmetric carbon atom; b) adding sufficient solvent in which the salt is poorly soluble; c) collecting the crystalline diamine MeSO 3 H salt. 1 1. The process of claim 10 comprising the steps of: a) in step a of claim 10, dissolving the stereoisomers of the diamine in an anhydrous organic solvent solution before and when the MeSO 3 H is added; b) in step b of claim 10, said solvent in which the salt is poorly soluble is anhydrous and its volume is greater than the volume of the original anhydrous organic solvent (step a of the present claim); c) after step b of claim 10, heating and distilling the solution of salt and said solvent until the volume reduction from distillation is 20% or more, and holding the distillation temperature to a maximum of about 80°C; d) after step c of the present claim, cooling said heated and distilled mixture, and lowering the temperature to between about 60°C to 20°C; and e) after step d of the present claim, adding previously prepared seed salt and then cooling the resulting salt solution further by cooling to between about 40 to below -20°C, filtering said solution, and collecting the crystals. 12. The process of claim 1 1, comprising the steps, after step (e) of claim 11, of washing the crystals in cool (about 5°C to -10°C) THF after the crystals are filtered and drying the washed crystals. 13. The process of claim 12 wherein: said solvent in which the diamine is dissolved in before and when the MeSO 3 H is added is CH 2 C1 2 ; said solvent in which the salt is poorly soluble is THF and the volume of the THF is greater than the volume of original CH 2 C1 2 solvent; and said distillation temperature maximum is about 65°C, said process comprising the steps of: cooling said heated and distilled mixture to a temperature of about 45°C; after said seed salt is added, further cooling the resulting salt solution to between about 20°C to -10°C, and then filtering the solution; and after the crystals are filtered, washing the crystals in cool (about 0°C to -5°C ) THF, and then filtering the crystals again. 14. The process of claim 13 comprising the steps of: cooling said heated mixture to about 45°C for about 5 to 10 minutes; adding said seed salt and cooling the resulting salt solution to about 28°C for about 5 to 10 minutes, then cooling the solution to about 20°C in about 5 min., holding the solution at 20°C for about 1 hour, then cooling the solution to about -10 to -5°C in about 30 min.; and filtering and then washing the crystals with 0°C THF and drying the crystals at about 50°C.

Inventors: RUNGE THOMAS A, RUNGE, THOMAS, A.
Applicants: RUNGE THOMAS A, UPJOHN CO, PHARMACIA & UPJOHN COMPANY, RUNGE, THOMAS, A.
Application year: 1999
Main classification: C07D207
IPC codes: C07D207